Doctors and researchers have known about a biomarker known as MTAP deletion for many years. But now they’re learning what role this gene plays in lung cancer and other tumors. Long ago, this genetic alteration was thought to be just collateral damage in tumors, but now researchers are uncovering its influence on tumors. It turns out there are some advantages for a tumor to have this MTAP gene loss. This new understanding means new medications can likely be developed to open a new weak point in the cancer to allow for targeted therapy. 

Guest:

Jordi Rodon Ahnert, MD, PhD, medical oncologist at MD Anderson Cancer Center in Houston, Texas.

Show Notes for this episode | Transcript | Watch the video podcast